Karl Fredrik Sjövall
Presidente en ZICCUM AB .
Origen de la red de primer grado Karl Fredrik Sjövall.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
13
| Public Company | Medical Specialties | 13 |
10
| Public Company | Miscellaneous Commercial Services | 10 |
10
| Public Company | Medical Specialties | 10 |
Emollivet AB
1
| Private Company | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Karl Fredrik Sjövall a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| University of Lund | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree Masters Business Admin Masters Business Admin | |
| University of Gothenburg | College/University | Graduate Degree Graduate Degree Undergraduate Degree Doctorate Degree | |
| INHALATION SCIENCES SWEDEN AB | Medical Specialties | Director of Finance/CFO Director of Finance/CFO Founder Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Comptroller/Controller/Auditor | |
| STAYBLE THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Founder Director of Finance/CFO | |
| Chalmers University of Technology | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| ACUCORT AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chief Executive Officer | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director of Finance/CFO | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Director/Board Member Public Communications Contact Comptroller/Controller/Auditor | |
HemoCue AB
 HemoCue AB Medical SpecialtiesHealth Technology HemoCue AB develops, produces, and markets medical diagnostic products for point of care testing. Its solutions include hematology, diabetes, data management and connectivity solutions, and accessories and consumables. The company was founded in 1982 and is heaquartered in Angelholm, Sweden. | Medical Specialties | Sales & Marketing Corporate Officer/Principal | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Novozymes Biopharma Sweden AB
 Novozymes Biopharma Sweden AB BiotechnologyHealth Technology Part of Repligen Corp., Novozymes Biopharma Sweden AB operates as a contract manufacturer of biological products. The company is based in Lund, Sweden. The CEO of the Swedish company is Harald Skogman. Novozymes Biopharma Sweden was acquired by Repligen Corp. from Novozymes A/S on December 20, 2011 for $29.02 million. | Biotechnology | Corporate Officer/Principal Sales & Marketing | |
Eribis Pharmaceuticals AB
 Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Corporate Officer/Principal Chairman | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Private Equity Investor | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member Director/Board Member | |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Investment Managers | Chief Executive Officer Private Equity Investor | |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CELLAVISION AB | Medical Specialties | Public Communications Contact Sales & Marketing | |
| KCIF Fund Management AB | Chief Executive Officer Chief Executive Officer | ||
| CHORDATE MEDICAL HOLDING AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SENSIDOSE AB | Electronic Equipment/Instruments | Comptroller/Controller/Auditor Chairman | |
| University of Uppsala | College/University | Masters Business Admin Corporate Officer/Principal | |
| KD Incentive AB | Director/Board Member Director/Board Member | ||
| Royal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
| Sumit System AB | Chief Executive Officer Chairman | ||
| INVOICERY GROUP AB | Investment Managers | Founder | |
| UPGRADE INVEST NORDIC AB | Financial Conglomerates | Chairman | |
| ROLLING OPTICS HOLDING AB | Miscellaneous Manufacturing | Director/Board Member | |
| TURA GROUP AB | Electronics/Appliance Stores | Founder | |
| RENEWABLE VENTURES NORDIC AB | Investment Managers | Chairman | |
| Universidad Católica del Norte | College/University | Masters Business Admin | |
| Stockholm School of Economics | College/University | Undergraduate Degree | |
Råsunda förvaltning AB
 Råsunda förvaltning AB Financial ConglomeratesFinance Råsunda Förvaltning AB buys, sells, and manages real estate. It also engages in securities trading and related business. The company was founded on October 22, 2007 and is headquartered in Sundbyberg, Sweden. | Financial Conglomerates | Chairman | |
| Acuma Invest AB | Chairman | ||
| ORASOLV AB | Medical/Nursing Services | Director/Board Member | |
| Histolab Products AB | Director/Board Member | ||
| EKF DIAGNOSTICS HOLDINGS PLC | Medical Specialties | Corporate Officer/Principal | |
| Råsunda Advice AB | Chairman | ||
| BIO VITOS PHARMA AB | Medical Specialties | Director/Board Member | |
Q-Med AB
 Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Medical Specialties | Corporate Officer/Principal | |
| BOULE DIAGNOSTICS AB | Medical Specialties | Director/Board Member | |
EQT Partners AB
 EQT Partners AB Investment ManagersFinance EQT Partners AB (EQT Partners) is a private equity subsidiary of EQT AB founded in 1994 by Yngve Conni Jonsson. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Private Equity Analyst | |
| ONCOZENGE AB | Pharmaceuticals: Major | Director of Finance/CFO | |
| MINESTO AB | Alternative Power Generation | Chief Operating Officer | |
| Ocean Energy Centre | Corporate Officer/Principal | ||
| Ecoera | Chief Executive Officer | ||
| Offshoreväst | Corporate Officer/Principal |
Estadísticas
Internacional
| Suecia | 48 |
| Noruega | 2 |
| Chile | 2 |
| Reino Unido | 2 |
Sectorial
| Health Technology | 19 |
| Finance | 10 |
| Consumer Services | 8 |
| Commercial Services | 3 |
| Electronic Technology | 2 |
Operativa
| Director/Board Member | 129 |
| Corporate Officer/Principal | 57 |
| Director of Finance/CFO | 27 |
| Chairman | 26 |
| Chief Executive Officer | 25 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Sten Gunnar Otto Skolling | 32 |
| Michael Owens | 25 |
| Gunilla Lundmark | 20 |
| Ola Flink | 19 |
| Per Nilsson | 17 |
| Ann Gidner | 15 |
| Ola Camber | 15 |
| Clas Runnberg | 15 |
| Pontus Ottosson | 14 |
| Johny Humaloja | 10 |
| Kristian Kierkegaard | 9 |
| Mattias Münnich | 9 |
| Thomas Pålsson | 9 |
| Johnny Mattias Carlsson | 8 |
| Karin Cecilia Dahllöf | 8 |
- Bolsa de valores
- Insiders
- Karl Fredrik Sjövall
- Conexiones Empresas
